What happens when a new drug comes charging out of the launch gate? For Biogen Idec ($BIIB), it means a rethink of its real estate plans. Its fast-growing staff won't all fit in the new headquarters under construction in Cambridge, MA. Report
| Published: September 29, 2014 | Sponsored by: Covance
Industry spending on post-authorization studies belies the rapid changes occurring in Phase IV research, driven by an the demand for evidence of safety and effectiveness. Download this Special Report to learn how Phase IV research continues to transform.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!